Introduction:

Artificial Heart Lung Machines Market was valued at US$ 374.2 million in 2024 and is projected to grow at a CAGR of 5.3% to reach US$ 598.3 million by 2034.

Artificial heart lung machines, also known as a cardiopulmonary bypass machine (CBP) or heart-lung bypass machine, is a complex medical device that temporarily takes over the work of the heart and lungs during surgery or other medical procedures. It essentially circulates blood throughout the body, just like the heart does. This is done using a mechanical pump that pulls blood from the body, sends it through a circuit, and then returns it to the body. The machine also adds oxygen to the blood and removes carbon dioxide, similar to the lungs. This is done using an oxygenator, which is a special chamber that contains thin membranes that allow oxygen to pass from the air into the blood and carbon dioxide to pass from the blood into the air.

Artificial heart lung machines are most commonly used during open-heart surgery to repair or replace damaged heart valves or to bypass blocked coronary arteries. They are also used for other procedures that require the heart to be stopped, such as lung transplantation or some brain surgeries. During surgery, the patient is connected to such artificial heart lung machines through cannulas, which are thin tubes that are inserted into large blood vessels. The blood is then pumped through the machine and returned to the body. The surgeon can then operate on the heart while the machine keeps the patient's blood circulating and oxygenated.

Artificial heart lung machines are necessary to enable complex surgical procedures, provide stable surgery environment and support a failing heart while acting as a bridge for patients waiting for transplant. The growing number of heart surgeries, an aging population and more biocompatible designs are driving continuous growth in the artificial heart lung machines market.

Over 2 million individuals globally have open cardiac surgery to address a range of cardiac conditions. According to estimates from the Centre for Disease Control and Prevention (CDC), 20.1 million persons in the US over 20 have coronary artery disease (CAD), which necessitates open heart operations and, consequently, the use of artificial heart lung machines for diagnosis and treatment. In addition, the CDC estimates that heart disease claimed the lives of almost 697,000 Americans. This extensive use is driving up demand in the target market.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Drivers of the Artificial Heart Lung Machines Market:      

• Growing Demand for Surgical Procedures and increase in chronic cardiovascular illnesses: 

Cardiovascular diseases are the leading cause of death globally, and their prevalence is expected to increase in the coming years due to factors such as aging population, unhealthy lifestyles, and rising obesity rates. This is leading to a growing demand for open-heart surgeries, which require the use of artificial heart lung machines. These heart lung machines can also be used to provide temporary support to patients with respiratory failure, while other treatment options are explored.

As number of cases of diseases ranging from lung cancer, coronary artery blockades and brain tumours to complete heart or lung transplants is steadily increasing across the globe the demand for surgical treatment is also rising and directly driving the expansion of the artificial heart lung machines market. Minimally invasive surgeries are becoming increasingly popular due to their benefits for patients, such as shorter recovery times and less pain. However, these surgeries often require the use of specialized heart-lung machines, which is driving market growth.

Every year, more than 4600 lung transplants are carried out globally, with North America accounting for 55% of these procedures. There were 2,569 lung transplants performed in 2021, of which 506 were single and 2,063 were bilateral. The recipients who received the greatest number of transplants (1,171) were those who were 50–64 years old, followed by 933 recipients who were aged 65 years or older, and 440 recipients who were 18–49 years old.

• Growing Geriatric Population across the world:

As global populations are getting older there's a higher chance that they will experience health issues such as strokes, heart attacks and lung or brain trauma that require surgery involving stopping the original heart, blood transfusions etc. Older people are consistently at a higher risk of chronic disease, muscular degeneration and frequently immunocompromised. Hence the need for advanced biocompatible materials and infection resistant Artificial heart lung machines that improve the quality of patient care and act as support bridges for failing organs or transplant treatment are in heavy demand. An increase in global geriatric population is therefore a direct driver for the expansion of the target market.

• Technological Advancements: 

Manufacturers are constantly developing new and improved heart-lung machines with features such as reduced blood trauma, improved oxygenation, and longer pump life. There is a growing demand for the development of better infection resistance and compatibility in Artificial heart lung machines to cater to a diverse pool of patients especially those who have weaker veins and other anatomic differences. Development of next-generation oxygenators and pumps with integrated sensors which can monitor vital signs and blood parameters, potentially improving patient safety and treatment efficacy is also currently underway. These advancements are making heart lung machines more effective and safer for patients, which is driving market growth.

Restrains:

• High cost: One of the major restraints in the artificial heart lung machines market is the high cost of artificial heart lung machines. These machines can cost tens of thousands of dollars, which can be a burden for patients and healthcare providers alike.
• Limited availability: Another restraint is the limited availability of artificial heart lung machines. There is a shortage of these machines in many parts of the world, which can limit access to this life-saving technology.
• Lack of skilled medical professionals: Operating and maintaining artificial heart lung machines requires specialized skills and training. There is a shortage of qualified medical professionals who can operate these machines, which can further limit their use.
• Complications: Artificial heart lung machines can also lead to complications, such as bleeding, infection, and stroke. These complications can increase the cost of care and decrease the quality of life for patients.

Key Opportunities in Artificial Heart Lung Machines Market:

• Technological advancements: Innovations like miniaturization, improved biocompatibility of materials, and integrated monitoring systems are enhancing the efficacy and safety of these machines, creating opportunities for new product development. Integrating artificial intelligence into heart lung machines for automated functions, real-time data analysis, and predictive maintenance can improve efficiency and patient outcomes.
• Focus on minimally invasive surgeries: The growing preference for minimally invasive surgeries is furthering the development of smaller and more portable heart lung machines, opening up new avenues for growth of artificial heart lung machines market.
• Expanding applications: Beyond traditional cardiac surgeries, these machines are finding applications in lung transplants, ECMO therapies, and other critical care settings, broadening the market scope.

Artificial Heart Lung Machines Market is segmented based on based on by Type, by Application and Region.

Type Insight

• Single Roller Pump-  This segment currently holds the majority of the market share in the artificial heart lung machines market, accounting for around 60% of the global market and is expected to witness steady growth in the coming forecast period due to its lower initial cost, simpler design, ease of operation/maintenance as well as lesser susceptibility to air emboli.
• Double Roller Pump- This segment currently shows the fastest growth in the market and is expected to continue to grow in the coming years. It currently accounts for around 40% of the global market. Its advantages include lower hemolysis rates, continuous flow, which is beneficial for some patients and its application in a wider range of surgeries

Application Insights

• Cardiac Surgery- This is the largest and fastest-growing segment of the artificial heart lung machine market, accounting for over 50% of the market share. The increasing prevalence of cardiovascular diseases, such as coronary artery disease and heart valve disease, is driving the demand for cardiac surgery, which in turn is driving the demand for artificial heart lung machines.
• Lung Transplantation Operations- This segment is expected to grow at a significant CAGR over the forecast period, due to the increasing prevalence of chronic lung diseases, such as COPD and pulmonary fibrosis. The development of new lung preservation techniques and technologies is also expected to boost the growth of this segment.
• Acute Respiratory Failure Treatment- This segment is expected to witness moderate growth over the forecast period, driven by the increasing incidence of respiratory failure due to conditions such as pneumonia, ARDS, and sepsis. The development of portable and miniaturized artificial heart lung machines is expected to create new opportunities in this segment.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

 Artificial Heart Lung Machines Market Regional Insights:

On region the Artificial Heart Lung Machines Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

• North America market held the largest market shares of the Artificial Heart Lung Machines Market in 2022 and is estimated to witness a significantly high revenue share over the forecast period. This is due to the growing number of chronic heart diseases and organ transplant cases. Technological advancement of heart lung machines is another major growth driver.
• Asia Pacific market is estimated to witness fastest revenue share of the target market due to rapidly growing population fuelled by the rising cases of arterial blockages and degenerated heart valve muscles and a massive geriatric population who need diagnosis and treatment for chronic cardiovascular diseases and neural or pulmonary disorders. Increasing investment in healthcare research will drive demand for advanced bloodlines in this region.
• Europe has developed economies and well-established public healthcare measures; hence it maintains the second largest share of the Artificial heart lung machines Market. Demand for technologically advanced treatment procedures and patient oriented care will promote market expansion in coming years.
• Latin America has smaller market shares but offers significant potential for future growth due to expanding economies and investment in health care. Countries with large geriatric population have scope of holding substantial sections of the target market in the forecast period due to their recent investments in technical advancement of equipment and demand for quality care.
• Middle East & Africa: The Artificial Heart Lung Machines Market in this region is expected to witness significant growth in the coming years, driven by several factors such as the rapid advancement in technology and increase in respiratory and cardiovascular diseases. Growing access to donor organs will allow more transplants which in turn will drive the use of Artificial heart lung machines.

Report Scope:

Attribute	Details
Market Size 2024	US$  374.2 million
Projected Market Size 2034	US$ 598.3 million
CAGR Growth Rate	5.3%
Market Segmentation	By Type- Single Roller Pump and Double Roller Pump By Application- Cardiac Surgery, Lung Transplantation Operations, and Acute Respiratory Failure Treatment
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Artificial Heart Lung Machines Market report based on By Type, By Application and Region:

 Artificial Heart Lung Machines Market, By Type:

• Single Roller Pump
• Double Roller Pump

Artificial Heart Lung Machines Market, By Application:

• Cardiac Surgery,
• Lung Transplantation Operations
• Acute Respiratory Failure Treatment

Artificial Heart Lung Machines Market, By Region:

North America:

• U.S.
• Canada

Europe:

• Germany
• UK
• France
• Russia
• Italy
• Rest of Europe

Asia Pacific:

• China
• India
• Japan
• South Korea
• Rest of Asia Pacific

Latin America:

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa:

• GCC
• Israel
• South Africa
• Rest of Middle East & Africa

The key players operating the Artificial Heart Lung Machines Market includes, Medtronic Inc., Sorin Group, MAQUET GmbH & Co. KG, Terumo Corporation, R. Bard, Inc., Edwards Lifesciences LLC, Braile Biomedica, Inc., Tianjin Medical, SynCardia Systems, Inc., Jarvik Heart, Inc. and Others.

Recent Development:

• In June 2023, Maquet Getinge launched its CardioLife Assist device, an extracorporeal membrane oxygenator (ECMO) system designed for both adults and children. This system features an integrated heat exchanger and blood warmer, potentially simplifying patient care and improving temperature management.
• In June 2023, Medtronic unveiled its next-generation ECMO platform, the Heart-Lung Bypass System (HLBS). This system boasts advancements in miniaturization, portability, and automation, aiming to improve its suitability for various clinical settings and patient needs.
• In April 2023, Abbott announced the first implant of its HeartMate 3 LVAD with Rivacor pump in Europe. This next-generation device features a smaller size and enhanced blood flow characteristics, potentially improving patient outcomes and comfort.
• In July 2022, China's National Medical Products Administration (NMPA) approved the "heart" developed by Jiangsu Lemai Technology, an implantable left ventricular assist device (LVAD) powered by ferrofluids. This marks the first domestically produced LVAD to be approved in China, potentially improving accessibility for heart failure patients there.

• Medtronic Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sorin Group
• MAQUET GmbH & Co. KG
• Terumo Corporation
• R. Bard, Inc.
• Edwards Lifesciences LLC
• Braile Biomedica, Inc.
• Tianjin Medical
• SynCardia Systems, Inc.
• Jarvik Heart, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Preface
• Research Objectives
• Study Scope
• Years Considered for the study
• Assumptions
• Abbreviations

Research Methodology

• Research data
• Primary Data
  • Primary Interviews
  • Primary Breakdown
  • Key data from Primary Sources
  • Key Thickness Insights
• Secondary Data
  • Major Secondary Sources
  • Secondary Sources
• Market Estimation
• Top-Down Approach
  • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
• Bottom-Up Approach
  • Approach for estimating market share by Bottom-up Analysis (Demand Side)
• Market Breakdown and Data Triangulation
• Research Assumptions

Market Preview

• Executive Summary
• Key Findings—Global Outlook for medical carts Strategies
  • Key Questions this Study will Answer
  • Market Snippet, By Type
  • Market Snippet, By Application
  • Market Snippet, By Region
• Opportunity Map Analysis
• Executive Summary—3 Big Predictions

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restrains
  • Market Opportunities
  • Market Trends
• DR Impact Analysis
• PEST Analysis
• Porter’s Five Forces Analysis
• Opportunity Orbit
• Market Investment Feasibility Index
• Macroeconomic Factor Analysis

Market Segmentation, By Type, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Single Roller Pump
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Double Roller Pump
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Application, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Cardiac Surgery
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Lung Transplantation Operations
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Acute Respiratory Failure Treatment
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • France
    • Germany
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• GCC
• Israel
• South Africa
• Rest of Middle East

Competitive Landscape

• Heat Map Analysis
• Market Presence and Specificity Analysis

Company Profiles

• Medtronic Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sorin Group
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• MAQUET GmbH & Co. KG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Terumo Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• R. Bard, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Edwards Lifesciences LLC
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Braile Biomedica, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Tianjin Medical
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• SynCardia Systems, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Jarvik Heart, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

The Last Word

• Future Impact
• About Us
• Contact